What is HC Wainwright’s Estimate for BOLT Q1 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Bolt Biotherapeutics in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.34) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.38). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Separately, Stifel Nicolaus decreased their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research note on Tuesday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Price Performance

Shares of BOLT stock opened at $0.43 on Friday. The firm has a fifty day moving average of $0.47 and a two-hundred day moving average of $0.55. The firm has a market cap of $16.29 million, a P/E ratio of -0.25 and a beta of 0.94. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16.

Institutional Trading of Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BOLT. Citadel Advisors LLC acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at about $42,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics in the fourth quarter valued at approximately $27,000. Squarepoint Ops LLC bought a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at approximately $26,000. Millennium Management LLC acquired a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $25,000. Finally, FMR LLC lifted its holdings in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after purchasing an additional 28,773 shares during the last quarter. 86.70% of the stock is owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.